Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 16, 2009 02:00 ET | Source: Merrion Pharmaceuticals plc

Photo Release -- Merrion Announces License Agreement With Novo Nordisk to Develop Oral Formulation of GLP-1 Receptor Agonist(s) -- Novo Nordisk Makes Equity Investment in Merrion

DUBLIN, Ireland, Jan. 16, 2009 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals (IEX:MERR) and Novo Nordisk A/S (NYSE:NVO), a world leader in diabetes, have entered into a Development and License Agreement...
January 16, 2009 02:00 ET | Source: Merrion Pharmaceuticals plc

Merrion Announces License Agreement With Novo Nordisk to Develop Oral Formulation of GLP-1 Receptor Agonist(s) -- Novo Nordisk Makes Equity Investment in Merrion

DUBLIN, Ireland, Jan. 16, 2009 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals (IEX:MERR) and Novo Nordisk A/S (NYSE:NVO), a world leader in diabetes, have entered into a Development and License...
November 24, 2008 02:00 ET | Source: Merrion Pharmaceuticals plc

Photo Release -- Merrion Announces License Agreement With Novo Nordisk to Develop Oral Formulation of Insulin Analogues

DUBLIN, Ireland, Nov. 24, 2008 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals (IEX:MERR)and Novo Nordisk A/S (NYSE:NVO), a world leader in diabetes, have entered into a Development and License Agreement...
November 05, 2008 05:25 ET | Source: Merrion Pharmaceuticals plc

Merrion Pharmaceuticals Receives 2008 Frost & Sullivan Osteoporosis Technology Innovation of the Year Award

DUBLIN, Ireland, Nov. 5, 2008 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals (IEX:MERR), an international specialty pharmaceutical company, today announced that it has been awarded the Frost &...
July 18, 2008 02:00 ET | Source: Merrion Pharmaceuticals plc

Merrion Pharmaceuticals plc Announces Commencement of Next Stage of Oral Drug Research Collaboration Programme With Novo Nordisk

DUBLIN, Ireland, July 18, 2008 (PRIME NEWSWIRE) -- Merrion Pharmaceuticals today announced the continuation of an oral drug delivery research collaboration programme with Novo Nordisk. This follows on...